Following the final order issued by the Department of Justice (DOJ) and the Drug Enforcement Administration (DEA) to reschedule certain marijuana products from Schedule I to Schedule III of the Controlled Substances Act (CSA), the U.S. Department of the Treasury and the Internal Revenue Service (IRS) issued a press release on April 23, 2026, detailing the forthcoming tax guidance. This administrative shift carries substantial tax implications for clients operating in the cannabis space, directly impacting the application of the deduction disallowance under Section 280E of the Internal Revenue Code (I.R.C.).
For tax practitioners, analyzing the Treasury's initial statements against the DEA's regulatory recommendations is critical for effective tax planning in the coming filing seasons.
The Foundational Shift in I.R.C. § 280E Applicability
Historically, state-licensed cannabis businesses have been severely restricted by I.R.C. § 280E, which mandates that "[n]o deduction or credit shall be allowed for any amount paid or incurred during the taxable year in carrying on any trade or business if such trade or business (or the activities which comprise such trade or business) consists of trafficking in controlled substances (within the meaning of schedule I and II of the Controlled Substances Act) which is prohibited by Federal law or the law of any State in which such trade or business is conducted".
Because the DOJ's Final Order transfers FDA-approved marijuana products and marijuana subject to a qualifying state-issued medical license to Schedule III, the fundamental trigger for I.R.C. § 280E is removed for these specific operations. Treasury and the IRS formally recognized this in their April 23, 2026 release, stating that "rescheduling generally removes section 280E as a bar to claiming deductions and credits for businesses that as a result of the Final Order no longer traffic in Schedule I or II controlled substances under the CSA". The agencies anticipate this will yield "significant positive tax consequences for businesses in the medical marijuana industry".
Read more here
